Abstract:
Retinoblastoma, a pediatric ocular malignancy, presents significant challenges in comprehending its molecular underpinnings and targeted therapeutic approaches. The dysregulated activity of histone deacetylases (HDACs) has been associated with retinoblastoma pathogenesis, influencing critical cellular processes like cell cycle regulation or retinal ganglion cell apoptosis. Through their deacetylase activity, HDACs exert control over key tumor suppressors and oncogenes, influencing the delicate equilibrium between proliferation and cell death. Furthermore, the interplay between HDACs and the retinoblastoma protein pathway, a pivotal aspect of retinoblastoma etiology, reveals a complex network of interactions influencing the tumor microenvironment. The examination of HDAC inhibitors, encompassing both established and novel compounds, offers insights into potential approaches to restore acetylation balance and impede retinoblastoma progression. Moreover, the identification of specific HDAC isoforms exhibiting varying expression in retinoblastoma provides avenues for personalized therapeutic strategies, allowing for interventions tailored to individual patient profiles. This review focuses on the intricate interrelationship between HDACs and retinoblastoma, shedding light on epigenetic mechanisms that control tumor development and progression. The exploration of HDAC-targeted therapies underscores the potential for innovative treatment modalities in the pursuit of more efficacious and personalized management strategies for this disease.
摘要:
视网膜母细胞瘤,小儿眼部恶性肿瘤,在理解其分子基础和有针对性的治疗方法方面提出了重大挑战。组蛋白脱乙酰酶(HDAC)的活性失调与视网膜母细胞瘤的发病机制有关。影响关键细胞过程,如细胞周期调节或视网膜神经节细胞凋亡。通过它们的脱乙酰酶活性,HDAC对关键的肿瘤抑制因子和癌基因发挥控制作用,影响增殖和细胞死亡之间的微妙平衡。此外,HDAC和视网膜母细胞瘤蛋白通路之间的相互作用,视网膜母细胞瘤病因学的一个关键方面,揭示了影响肿瘤微环境的相互作用的复杂网络。HDAC抑制剂的检查,包括已建立的和新的化合物,提供了恢复乙酰化平衡和阻止视网膜母细胞瘤进展的潜在方法的见解。此外,在视网膜母细胞瘤中表现出不同表达的特定HDAC亚型的鉴定为个性化治疗策略提供了途径,允许针对个体患者概况进行干预。这篇综述集中在HDAC和视网膜母细胞瘤之间复杂的相互关系。阐明控制肿瘤发展和进展的表观遗传机制。对HDAC靶向疗法的探索强调了创新治疗方式在寻求更有效和个性化治疗这种疾病的策略方面的潜力。